Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of California, San Francisco
About this trial
Cancer-related fatigue (CRF) is a significant problem for cancer patients. This prospective, basic science, observational study will evaluate for changes in CRF associated with molecular characteristics prior to, during, and at the completion of non-investigational, standard-of-care, combined chemotherapy and radiation therapy (CCRT) and to develop and assess predictive models for CRF severity.
Eligibility criteria
Qualifiers
Participants have not received any prior treatment (i.e., cancer systemic therapies or radiation therapy) in the month except surgery or inductive Chemotherapy (CTX).
Participants receiving >= 15 fractions.
Participants is male or female and is >18 years of age on the day of signing the informed consent.
Ability to understand a written informed consent document.
Disqualifiers
Contraindication to phlebotomy for removal of approximately 50 mL of peripheral blood within 6 week period (Institutional Review Board (IRB) limit).
Trial design
Treatments tested in this trial
- Blood Specimen Collection
- Stool Specimen Collection
- Quality of Life (QOL) Questionnaires
Treatment groups
125 Participants
are divided into 1 treatment groupSponsors and collaborators
University of California, San Francisco
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov